In this podcast, Stephen Rose, MD, president and CEO of Houston Breast Imaging and a principal investigator of the 3-D tomosynthesis clinical trials in 2010, discusses the benefits of the new technology and what his practice learned when implementing the screening program.
[[{"type":"media","view_mode":"media_crop","fid":"11554","attributes":{"alt":"Stephen Rose","class":"media-image media-image-left","id":"media_crop_8501769795264","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"218","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: left;","title":" ","typeof":"foaf:Image"}}]]In February 2011, the FDA approved the first X-ray mammography system that provides 3-D images for breast cancer screening and diagnosis, Hologic’s Selenia Dimensions. The 3-D tomosynthesis is being offered in fewer than two dozen locations in the U.S., and among them is Houston Breast Imaging in Texas.
In this podcast, Stephen Rose, MD, president and CEO of Houston Breast Imaging and a principal investigator of the 3-D tomosynthesis clinical trials in 2010, discusses the benefits of the new technology and what his practice learned when implementing the screening program. .
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.